S. Foti

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial.

S. Barni, V. Torri, S. Novello, 2014, The Lancet. Oncology.

Does immunotherapy change the treatment paradigm in metastatic gastric cancer?

S. Cascinu, M. Scartozzi, E. Mazza, 2022, Medical Oncology.

A real‐world comparison of docetaxel versus abiraterone acetate for metastatic hormone‐sensitive prostate cancer

R. V. D. van den Bergh, G. Gandaglia, I. Tsaur, 2021, Cancer medicine.

Treatment of Metastasized Prostate Cancer Beyond Progression After Upfront Docetaxel-A Real-world Data Assessment.

R. V. D. van den Bergh, G. Gandaglia, I. Tsaur, 2020, European urology focus.

Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).

J. Machiels, F. D. De Braud, Z. Tsuchihashi, 2022, Journal of Clinical Oncology.

Skin DVHs predict cutaneous toxicity in Head and Neck Cancer patients treated with Tomotherapy.

C. Fiorino, G. Cattaneo, R. Calandrino, 2018, Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics.

Immunotherapy in small bowel adenocarcinoma: a potential role?

S. Cascinu, E. Mazza, S. Cereda, 2023, Immunological Medicine.

Randomized proteomic stratified phase III study of second-line erlotinib (E) versus chemotherapy (CT) in patients with inoperable non-small cell lung cancer (PROSE).

S. Barni, V. Torri, S. Novello, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Could the association of sunitinib and stereotactic ablative radiotherapy lead to abscopal effect in metastatic renal cell carcinoma?

G. Conte, N. Muzio, A. Fodor, 2022, Journal of Clinical Images and Medical Case Reports.